Bard Associates Inc. Sells 13,565 Shares of Abaxis Inc (ABAX)

Bard Associates Inc. lowered its stake in shares of Abaxis Inc (NASDAQ:ABAX) by 68.9% during the second quarter, HoldingsChannel.com reports. The fund owned 6,135 shares of the medical research company’s stock after selling 13,565 shares during the period. Bard Associates Inc.’s holdings in Abaxis were worth $509,000 as of its most recent SEC filing.

Several other institutional investors also recently bought and sold shares of ABAX. Zurcher Kantonalbank Zurich Cantonalbank increased its position in shares of Abaxis by 154.3% during the first quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,085 shares of the medical research company’s stock worth $147,000 after acquiring an additional 1,265 shares during the period. SG Americas Securities LLC purchased a new stake in shares of Abaxis during the first quarter worth $181,000. Her Majesty the Queen in Right of the Province of Alberta as represented by Alberta Investment Management Corp purchased a new stake in shares of Abaxis during the second quarter worth $208,000. Tiedemann Advisors LLC purchased a new stake in shares of Abaxis during the first quarter worth $213,000. Finally, Northwest Bancshares Inc. purchased a new stake in shares of Abaxis during the first quarter worth $222,000. 90.23% of the stock is currently owned by institutional investors and hedge funds.

A number of research firms have recently weighed in on ABAX. Zacks Investment Research lowered Abaxis from a “buy” rating to a “hold” rating in a research report on Tuesday, July 24th. Sidoti reaffirmed a “neutral” rating on shares of Abaxis in a research report on Thursday, May 31st. One research analyst has rated the stock with a sell rating, nine have issued a hold rating, one has given a buy rating and one has assigned a strong buy rating to the company. The stock presently has a consensus rating of “Hold” and a consensus target price of $67.00.

NASDAQ:ABAX opened at $83.00 on Friday. The firm has a market capitalization of $1.90 billion, a P/E ratio of 64.34, a price-to-earnings-growth ratio of 5.51 and a beta of 1.43. Abaxis Inc has a 12 month low of $43.66 and a 12 month high of $83.98.

Abaxis Company Profile

Abaxis, Inc develops, manufactures, markets, and sells portable blood analysis systems for use in human or veterinary patient care to provide rapid blood constituent measurements for clinicians worldwide. It operates in two segments, Medical Market and Veterinary Market. The company offers Piccolo chemistry analyzers with rapid blood constituent measurements for use in human patient care; and Piccolo profiles that are single-use medical reagents.

See Also: Exchange-Traded Funds (ETFs)

Want to see what other hedge funds are holding ABAX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Abaxis Inc (NASDAQ:ABAX).

Institutional Ownership by Quarter for Abaxis (NASDAQ:ABAX)

Receive News & Ratings for Abaxis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abaxis and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply